Acalabrutinib-Based Regimens Continue to Top Obinutuzumab Plus Chemotherapy in Treatment-Naïve CLL
June 4th 2022With roughly 5 years of follow-up, outcomes were more favorable with acalabrutinib with or without obinutuzumab vs obinutuzumab and chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia.
Read More
Sacituzumab Govitecan Reduces Risk of Disease Progression in HR+/HER2- Metastatic Breast Cancer
June 4th 2022A 34% reduction in the risk of disease progression was observed with sacituzumab govitecan vs standard chemotherapy as treatment of patients with hormone-receptor-positive and HER2-negative metastatic breast cancer.
Read More
Hyper-CVAD With Blinatumomab and Inotuzumab Shows High Efficacy in Ph-Negative B-Cell ALL
June 4th 2022The probability of minimal residual disease negativity and complete remission in patients who received hyper-CVAD with blinatumomab and inotuzumab is higher compared with hyper-CVAD and blinatumomab alone.
Read More
Adjuvant Everolimus Reduces Risk of Recurrence or Death in High-Risk RCC
June 4th 2022Results from the phase 3 EVEREST trial presented during the 2022 ASCO Annual Meeting reveal the relapse-free survival advantage of using adjuvant everolimus over placebo in patient with high-risk renal cell carcinoma.
Read More
Six-Year Survival Extends With Brentuximab Vedotin Plus Chemotherapy in Hodgkin Lymphoma
June 4th 2022Therapy with brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine lead to a significant reduction in the risk of death vs doxorubicin, bleomycin, vinblastine, and dacarbazine, in patients with previously untreated stage III/IV classical Hodgkin lymphoma.
Read More
Pembrolizumab With Ramucirumab Boosts Survival Vs SOC in ICI-Resistant NSCLC
June 3rd 2022The use of pembrolizumab plus ramucirumab to treat non–small cell lung cancer in immune checkpoint inhibitor resistant patients showed better overall survival versus standard of care regimens in the Lung-MAP nonmatched phase 2 substudy S1800A.
Read More
Nimotuzumab Plus Chemotherapy Extends OS in KRAS Wild-Type Advanced Pancreatic Cancer
June 3rd 2022The combination of nimotuzumab and gemcitabine extended overall survival in patients with KRAS wild-type advanced pancreatic cancer, especially in those who did not need surgery for obstruction of a pancreatic bile duct
Read More
Hispanic Pediatric Patient With Neuroblastoma Show Worse Overall Survival
May 27th 2022After identifying a survival disparity among non-White Hispanic patients with pediatric neuroblastoma, investigators will next examine the interaction of survival and race, ethnicity, and poverty, acknowledging the intersectionality of these factors due to structural racism in the United States.
Read More
Mitomycin Gel Maintains QOL in Patients With Low Grade Non-Muscle Invasive Bladder Cancer
May 16th 2022Health-related quality-of-life outcomes were maintained among patients with low grade non-muscle invasive bladder cancer who were treated with UGN-102, a chemoablative reverse thermal gel as a primary approach in the single-arm phase 2b Optima II trial.
Read More
Infigratinib Demonstrates Activity and Tolerability of FGFR Inhibition in Urothelial Carcinoma
May 16th 2022Interim results from a biomarker-informed preoperative study of infigratinib demonstrated substantial activity and tolerability in patients with localized upper tract urothelial carcinoma, according to findings of a phase 1b trial.
Read More
Results of CG0070 Combined With Pembrolizumab in BCG-Unresponsive NMIBC
May 16th 2022Roger Li, MD, shares the results of the phase 2 CORE1 clinical trial, which evaluated CG0070 in combination with pembrolizumab for the treatment of patients with Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer.
Watch
Added Darolutamide Does Not Increase Toxicity With ADT/Docetaxel in mHSPC
May 16th 2022Darolutamide plus androgen deprivation therapy and docetaxel was not associated with an increase in incidence or severity of adverse events versus androgen deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.
Read More